Developpment of small molecules to prolong the protective effect of the Integrated Stress Response InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting iRhom2 for better treatment of autoimmune diseases SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling. Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases. drug …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

199 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing Oral Therapy for Neuropsychiatric and Neurodegenerative Diseases. Vesper Bio is a Danish clinical stage biotech company headquartered in Copenhagen, developing new disease-modifying treatments for people with neuropsychiatric and neurodegenerative diseases. We do this by a novel approach, targeting sortilin. We are developing first-in-class small molecule sortilin inhibitors for a number of critical unmet medical needs, such as mood disorders and frontotemporal dementia. Vesper Bio's investigational new drug candidate VES001, is a first-in-class, oral, brain-penetrant small molecule sortilin inhibitor in clinical development. It is being investigated as a potential disease-modifying therapy for both neuropsychiatric disease and frontotemporal dementia caused by …

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering personalized medicine in epigenetics Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey. The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented …

86 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing novel treatments at the forefront of oncology Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transcribing For Better Lives Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAheadTM, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAheadTM mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Axonis Therapeutics is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter …

128 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Delta4 is a Vienna-based biotech startup driving the forefront of digital drug discovery and development. Delta4 is driving the forefront of digital drug discovery and development. We leverage a proprietary computational analytics platform "Hyper-C", combining straightforward biomedical testing and clinical validation of candidate drugs. Our unique approach integrates iterative big data/in silico and experimental screens, offering the most efficient matching of clinical indications and compound/drug effects. drug repositioning, drug discovery, compounds, orphan diseases, indication expansion, AI, and omics

178 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Translating Complex Biology into Breakthrough Medicines InterAx is redefining drug discovery by understanding treatment impact on diseases before pre-clinical trials begin, an analysis traditionally inaccessible to very early programs. Focusing on GPCR small molecules, the Deep SignalTM platform enables superior optimization of drug candidates, leading to differentiated drugs with higher efficacy and safety and lower clinical failure rates. InterAx’s three-asset portfolio demonstrates this impact, including a biologically differentiated GLP-1 asset that addresses the challenges seen with small-molecule competitors, a partnered GIP program, as well as an innovative ACKR3 program driven by unique target understanding. With four additional targets identified, the …

131 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering drug discovery company exploiting cutting edge technologies to create best-in-class small molecule medicines C4XD is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‐leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD …

295 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

www.aukera-tx.com Aukera Therapeutics is a spin-off from the Biozentrum at the University of Basel, developing the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. We pair deep mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets. Our lead program focuses on rare neurological disorders such as Tuberous Sclerosis. Future applications of RAPTOR inhibitors include neurodegenerative, metabolic, and age-related diseases.

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Allosteric modulators for Human Health Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial …

59 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

From Sea to Pharmacy Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AlgoTx develops novel therapeutic solutions for complex pain AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making …

182 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

CNS/PNS - In vitro - In vivo - Drug Development Neuro-Sys is a research-intensive and innovative organisation specialising in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields. We provide pharmacological profiles of lead compounds and explore their underlying mechanism of action and studies to determine the neuroprotective activity. We’re dedicated to providing high-level technical expertise in a collaborative relationship with our clients and accompany you along the drug development stages, from preclinical to clinical. Our expertise: › Alzheimer’s disease (AD) › Parkinson’s …

92 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. FRAXA Research Foundation is a national 501c3 nonprofit organization. FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments. Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders. FRAXA also supports families affected by Fragile X syndrome and raises …

59 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflammatory diseases Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, AramcholTM, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide. Our corporate headquarters is located in Tel Aviv, Israel. For more information about Galmed, please visit our website at: www.galmedpharma.com

67 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

NEW FRONTIERS IN NEUROSCIENCE Neurentis PLC is a late-clinical stage UK specialty pharma company, focusing on neuroscience and specialising in the development of novel treatments for mental health and other neurological and psychiatric diseases. Our product pipeline is balanced with an advanced lead drug for the treatment of Treatment-Resistant Depression (TRD) in the last stages of drug development as well as earlier stage drug candidates in collaboration with research institutions and other companies. The company is run by experienced ex-pharma industry executives, with more than 35 years’ experience in the sector each. The company’s low-risk commercial strategy is to commercialize …

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

284 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

www.xspraypharma.com Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval …

76 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapies for neurodegenerative diseases Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such …

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives by accelerating innovation in cardiometabolic health Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. …

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

234 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

283 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mersana Therapeutics is now a part of Day One Biopharmaceuticals. For more information visit: https://www.dayonebio.com At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline …

135 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bringing Precision Medicine to patients with Neurodevelopmental Disorders, including Autism Spectrum Disorder STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: …

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com. Nuclear Medicine & Nuclear Industry, Biotechnology, Pharmaceutical, …

220 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer

181 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing microRNA modulators for diseases with unmet medical needs ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary platform that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in development for Myotonic Dystrophy Type 1 (DM1). DM1 …

67 similar entities Type: Startup Activities: biotech deeptech

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing next-generation radiotherapeutics to visualize and treat cancer Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 (177Lu) and Actinium-255 (255Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma …

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process …

424 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing a pipeline of first-in-class oral small molecule mPTP inhibitors as treatments for neurodegenerative diseases NRG Therapeutics is a clinical stage neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) and Parkinson’s. The company’s pipeline of first-in-class small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurons, reduce neuroinflammation, and improve motor function in preclinical disease models. …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A drug-discovery company focused on oncology, with a unique and powerful combination of expertise that sets us apart. Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I.

Evaluate your most effective drug candidates in vivo using objective & translational measurements in the brain. #EEG SynapCell is a Brain-focused biotechnology company that provides drug developers with robust and unbiased endpoints on drug efficacy in vivo, at the preclinical step. We use quantitative, EEG-based methods to longitudinally monitor a drug effect on translational models, following clinical-like protocols. Our capabilities include dose-response studies, pharmacodynamics, biomarker identification and modulation, disease-modifying assays, model phenotyping, as well as phenotypic screening for lead selection and validation. Our expertise in Neuroscience covers Epilepsy, Parkinson's disease, Essential Tremors as well as information processing defects such as …

126 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Connecting Brains WE ́RE NOT CURRENTLY HIRING MISSION & VALUES To serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. We value partnership and Integrity, we are ethical and responsible and show respect and compassion for our patients. R&D STRATEGY The successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. R&D is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. The advancements in science mean that more targeted, more (cost-)effective treatments are within …

183 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are a #TRPV1 focused company developing oral treatments for Type-2 #Diabetes & #Erythromelalgia PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.

59 similar entities Type: Startup Activities: biotech deeptech

As a member of ONO Group, Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

157 similar entities Type: SMB Activities: biotech deeptech Technologies: SaaS

Converting cancer to a manageable, chronic condition Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Collaborating with NIH & DoD to develop treatment options, targeting unmet needs in three multi-billion dollar markets. Virpax is pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. Designed for sustained release, Probudur delivers local anesthetic at the wound/incision site, effectively managing post-operative pain for an extended 96 hours. Collaborating through Cooperative Research and Development Agreements (CRADA) and partnering with prestigious institutions like the National Institute of Health/NCATS and U.S. Army Institute of Surgical Research/Department of Defense, we are committed to developing non-addictive treatments. Additionally, our involvement in the Epilepsy Therapy Screening Program (ETSP) underscores our …

145 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs …

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerate and secure your pipeline with preclinical expertise. in vitro & in vivo pharmacology services since 1991. ETAP-LAB – Preclinical CRO supporting therapeutic innovations for over 35 years ETAP-LAB is a recognized European preclinical CRO delivering efficient, cost-effective services to pharmaceutical, biotech/medtech, and nutraceutical companies across four key areas of expertise: • BRAINXPLORE – Expert in neurology and CNS disorders with integrated preclinical solutions for neurodegeneration and behavioral pharmacology. ​​ • SKINAXIS – Pharmacology efficacy in dermatology and skin disorders – supporting the development of drugs, regenerative therapies, and medical devices – with a strong track record of successful market …

104 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Scientist-to-Scientist 🔬 Porsolt is a long-established preclinical CRO, accredited by AAALAC and fully GLP compliant. 👨🏻‍🔬 With our Scientist-to-Scientist approach we support you at every step of the preclinical development process, providing the best scientific advice and offering tailored solutions to meet your needs. ✔️ We have a recognized international reputation for in vitro, ex vivo, and in vivo expertise in physiopathological models, customized procedures, histology, biomarkers, and tailored solutions for discovering treatments in over 10 different therapeutic areas. ✔️ We also offer services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing drugs for orphan CNS diseases Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from …

104 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Breakthrough safe and effective therapies for neuropsychiatric disorders Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nonclinical expert in cardiovascular pharmacology & electrophysiology and vascular functions PhysioStim is a French preclinical CRO dedicated to cardiovascular pharmacology and electrophysiology from discovery stages to clinical development. Whatever the therapeutic areas, we ensure robust and valuable preclinical data on cardiac and vascular activities and secondary pharmacology to secure in-vivo development and bring new safe therapies to patients. Thanks to our predictive and translational models, we define the POC of drug discovery, we investigate secondary pharmacology with on and off-target liabilities, and we address the safety purpose to build and support your IND submission (with mandatory and not mandatory assays). …

123 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Preclinical expertise in cardiovascular pharmacology for 25+ years. in vitro & in vivo services, by ETAP-LAB. SYNCROSOME by ETAP-LAB, preclinical services supporting therapeutic innovations for over 25 years Part of ETAP-LAB, a recognized European preclinical CRO delivering efficient, cost-effective services to pharmaceutical, biotech/medtech, and nutraceutical companies across four key areas: • SYNCROSOME – Cardiovascular & cardiorespiratory pharmacology, with 25+ years of international expertise. • BRAINXPLORE – Expert in neurology and CNS disorders with integrated preclinical solutions for neurodegeneration and behavioral pharmacology. ​​ • SKINAXIS – Pharmacology efficacy in dermatology and skin disorders – supporting the development of drugs, regenerative therapies, …

125 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Smart molecules for Neurodegenerative and Rare disorders Spin-off of the University of the Basque Country and Biogipuzkoa Health Research Institute. Focused on developing First in Class drugs for Neurodegenerative and Rare Diseases. First program in lead optimisation for Retinitis Pigmentosa (RP), and four programs in lead nomination for DMD, DM1, ALS and AD. The lead compounds normalise calcium levels and protect from oxidative stress damage Smart molecules for Neurodegenerative and Rare disorders, Drug development, and Retinitis Pigmentosa

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are reimagining the entire drug discovery process from first principles with an AI-first approach. Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease Drug Discovery and Design, machine learning, research, engineering, chemistry, and biology

208 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I.

The Specialist in CNS Drug Development Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results …

87 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory diseases InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies …

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology